Recent study finds that PEA supplementation may help alleviate migraine symptoms
A PEA supplement from Gencor was shown to reduce the duration of migraines as a well as severity.
Photo © AdobeStock.com/Artem Furman
A recent study1 found that supplementation with palmitoylethanolamide (PEA), marketed as Levagen+ by Gencor, may help to reduce the discomfort and duration of migraines. In the study 80 subjects were instructed to take either 600 mg of PEA or a placebo upon commencement of migraine symptoms. After taking the dose, subjects were asked to record a visual analogue scale (VAS) for pain every 30 min for 4 h or until the migraine resolved. If the migraine symptoms did not resolve two hours after taking the first dose, subjects were instructed to take a second dose.
Results showed that supplementation with PEA resolved significantly more migraines after two and eight hours compared to placebo. Subjects taking PEA also took significantly less rescue medication compared to placebo. Both groups experienced significant reductions in VAS scores from baseline at 30 and 60 minutes after supplementation, with no significant differences between the two groups. However, the group taking PEA did see significantly greater changes in VAS scores from baseline at 1.5 and 4 hours, compared to placebo.
“The results of this study further backs PEA’s clinically validated benefits for its analgesic and inflammatory properties in addition to its neuroprotective effects,” said R.V. Venkatesh, co-founder and managing director at Gencor, in a press release. “We are thrilled about the promising results and potential of Levagen+ to support those who suffer from migraine.”
Gencor’s Levagen+ uses LipiSperse delivery technology from Pharmako Biotechnologies, which the company says makes the ingredient more bioavailable.
Reference
- Briskey, D.; Skinner, R.; Smith, C.; Rao, A. Effectiveness of palmitoylethanolamide (Levagen+) compared to a placebo for reducing pain, duration, and medication use during migraines in otherwise healthy participants—A double-blind randomised controlled study. Pharmaceuticals. 2024, 17(2), 145. DOI: 10.3390/ph17020145
